Navigation Links
Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma
Date:6/7/2008

Lugano, Switzerland June 7, 2008 The Cancer and Leukemia Group B (CALGB) today announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab. Of the 61 patients in the study, 44 percent achieved a complete response and 26 percent had a partial response. The data were presented at the 10th International Conference on Malignant Lymphoma (ICML).

The results of this open label study suggest that adding galiximab to rituximab may be a promising regimen for patients with follicular lymphoma (FL), a common type of non-Hodgkin lymphoma (NHL), and that further study is warranted. The objective of the CALGB-coordinated study is to determine the overall response rate (ORR) and time-to-progression of the disease after treatment with a combined regimen of galiximab and rituximab. At this point, however, it is too early to assess the time-to-progression endpoint.

"Most non-Hodgkin lymphoma patients receive rituximab, either as a single agent or in combination with chemotherapy," said Myron Czuczman, M.D., Roswell Park Cancer Institute, principal investigator of this study. "Now, 'biologic' agents are being studied in combination to assess the efficacy of dual antibody therapies as potential alternatives to chemotherapy-based regimens."

Patients enrolled in the study had been diagnosed with CD20-positive FL but had not received treatment for the disease. Study patients were given galiximab plus rituximab together once a week for four weeks and then every two months for the next eight months. This "extended induction" schedule was chosen based on results from an earlier Swiss (SAKK) trial using the same schedule with single-agent rituximab. Thirteen percent of patients reported a grade 3 adverse event; no grade 4 toxicities were associated with this combination immunotherapy regimen.

Galiximab is an anti-CD80 monoclonal antibody that has been studied as a single-agent in previously treated FL and in combination with rituximab against relapsed FL. The CD80 molecule is found on the surface of activated macrophages, dendritic cells and cells from various subtypes of NHL. Galiximab's potential mechanisms of action include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and possible immunomodulatory effects on host effector cells affecting the tumor microenvironment.


'/>"/>

Contact: Rachi Govil
rachi.govil@offspringpr.com
212-798-9827
Offspring PR
Source:Eurekalert

Related biology news :

1. Human RecQ helicases, homologous recombination and genomic instability
2. Abnormal fat metabolism underlies heart problems in diabetic patients
3. A new radiation therapy treatment developed for head and neck cancer patients
4. Device helps patients survive, regain function til transplant
5. Diet support helps chronic kidney patients
6. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
7. Doctors learn to control their own brains pain responses to better treat patients
8. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
9. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
10. New class of drug offers hope to treatment-resistant AIDS patients
11. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... biological outbreak is about to be eliminated, said Lyle Probst, President, CEO and ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... Department of Financial Services (NYS DFS) cybersecurity regulations have transitioned into ... and insurance organizations operating in the state (“Covered Entities”) to conduct an ...
(Date:9/18/2017)... MONTREAL , Sept. 18, 2017   Montrium , a ... announced an exciting new partnership with a groundbreaking non-profit research organization, ... ... for MDMA-assisted psychotherapy studies for PTSD ... FDA has recently granted Breakthrough Therapy Designation to MDMA for the ...
Breaking Biology Technology: